Tags

Type your tag names separated by a space and hit enter

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Respir Med. 2008 Sep; 102(9):1248-56.RM

Abstract

RATIONALE

Although the economic burden of COPD has gained attention in recent years, data on the costs of COPD among U.S. Medicare beneficiaries are lacking.

METHODS

This study used administrative claims and eligibility records from a large U.S. multi-state Medicare managed care database. Study patients were 65+ years of age with paid claims during 2004. The COPD cohort comprised patients with 1+ inpatient/ER claims or 2+ outpatient claims (>30 days apart) for COPD (ICD-9-CM codes 491.xx, 492.x, 496). The comparison cohort included patients without COPD matched 3:1 to the COPD cohort on age, sex, enrollment months, and Medicare plan. Excess costs of COPD were estimated as the difference in overall health plan payments between the two cohorts during 2004. Attributable costs were calculated using medical claims with listed diagnoses of COPD or other respiratory-related conditions and pharmacy claims for respiratory medications.

RESULTS

A total of 8370 patients were included in the COPD cohort and were matched to 25,110 comparison cohort patients. For both groups, mean (SD) age was 78 (8) years, 54% were female, and duration of eligibility was 11 (2) months. COPD patients were more likely to utilize healthcare services and had excess total healthcare costs about $20,500 higher (P<0.0001) than the comparison cohort. Comorbidities were high in the COPD cohort, accounting for 46% of the observed excess cost. The attributable cost of COPD averaged about $6,300; other respiratory-related costs averaged about $4,400.

CONCLUSION

In this U.S. Medicare managed care population, COPD posed a substantial burden in terms of both respiratory-related and total healthcare costs. A comparison of these cost-of-illness estimates to those for elderly COPD patients in other countries would be of great interest, given the increasing age of populations in most Western countries.

Authors+Show Affiliations

Boston Health Economics, Inc., 20 Fox Road, Waltham, MA 02451, USA. jmenzin@bhei.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18620852

Citation

Menzin, Joseph, et al. "The Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in a U.S. Medicare Population." Respiratory Medicine, vol. 102, no. 9, 2008, pp. 1248-56.
Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med. 2008;102(9):1248-56.
Menzin, J., Boulanger, L., Marton, J., Guadagno, L., Dastani, H., Dirani, R., Phillips, A., & Shah, H. (2008). The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respiratory Medicine, 102(9), 1248-56. https://doi.org/10.1016/j.rmed.2008.04.009
Menzin J, et al. The Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in a U.S. Medicare Population. Respir Med. 2008;102(9):1248-56. PubMed PMID: 18620852.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. AU - Menzin,Joseph, AU - Boulanger,Luke, AU - Marton,Jeno, AU - Guadagno,Lisa, AU - Dastani,Homa, AU - Dirani,Riad, AU - Phillips,Amy, AU - Shah,Hemal, Y1 - 2008/07/11/ PY - 2007/04/19/received PY - 2008/03/31/revised PY - 2008/04/06/accepted PY - 2008/7/16/pubmed PY - 2009/8/15/medline PY - 2008/7/16/entrez SP - 1248 EP - 56 JF - Respiratory medicine JO - Respir Med VL - 102 IS - 9 N2 - RATIONALE: Although the economic burden of COPD has gained attention in recent years, data on the costs of COPD among U.S. Medicare beneficiaries are lacking. METHODS: This study used administrative claims and eligibility records from a large U.S. multi-state Medicare managed care database. Study patients were 65+ years of age with paid claims during 2004. The COPD cohort comprised patients with 1+ inpatient/ER claims or 2+ outpatient claims (>30 days apart) for COPD (ICD-9-CM codes 491.xx, 492.x, 496). The comparison cohort included patients without COPD matched 3:1 to the COPD cohort on age, sex, enrollment months, and Medicare plan. Excess costs of COPD were estimated as the difference in overall health plan payments between the two cohorts during 2004. Attributable costs were calculated using medical claims with listed diagnoses of COPD or other respiratory-related conditions and pharmacy claims for respiratory medications. RESULTS: A total of 8370 patients were included in the COPD cohort and were matched to 25,110 comparison cohort patients. For both groups, mean (SD) age was 78 (8) years, 54% were female, and duration of eligibility was 11 (2) months. COPD patients were more likely to utilize healthcare services and had excess total healthcare costs about $20,500 higher (P<0.0001) than the comparison cohort. Comorbidities were high in the COPD cohort, accounting for 46% of the observed excess cost. The attributable cost of COPD averaged about $6,300; other respiratory-related costs averaged about $4,400. CONCLUSION: In this U.S. Medicare managed care population, COPD posed a substantial burden in terms of both respiratory-related and total healthcare costs. A comparison of these cost-of-illness estimates to those for elderly COPD patients in other countries would be of great interest, given the increasing age of populations in most Western countries. SN - 0954-6111 UR - https://www.unboundmedicine.com/medline/citation/18620852/The_economic_burden_of_chronic_obstructive_pulmonary_disease__COPD__in_a_U_S__Medicare_population_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(08)00143-1 DB - PRIME DP - Unbound Medicine ER -